133 related articles for article (PubMed ID: 31628917)
21. Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control.
Wible DJ; Parikh Z; Cho EJ; Chen MD; Mukhopadhyay S; Dalby KN; Varadarajan S; Bratton SB
bioRxiv; 2023 Mar; ():. PubMed ID: 36993747
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of c-Rel DNA binding is critical for the anti-inflammatory effects of novel PIKfyve inhibitor.
Terajima M; Kaneko-Kobayashi Y; Nakamura N; Yuri M; Hiramoto M; Naitou M; Hattori K; Yokota H; Mizuhara H; Higashi Y
Eur J Pharmacol; 2016 Jun; 780():93-105. PubMed ID: 27001378
[TBL] [Abstract][Full Text] [Related]
23. Mammalian cell morphology and endocytic membrane homeostasis require enzymatically active phosphoinositide 5-kinase PIKfyve.
Ikonomov OC; Sbrissa D; Shisheva A
J Biol Chem; 2001 Jul; 276(28):26141-7. PubMed ID: 11285266
[TBL] [Abstract][Full Text] [Related]
24. B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibition.
Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Xu T; Rothberg J; Lichenstein H
Autophagy; 2017 Jun; 13(6):1082-1083. PubMed ID: 28350209
[TBL] [Abstract][Full Text] [Related]
25. The phosphoinositide kinase PIKfyve is vital in early embryonic development: preimplantation lethality of PIKfyve-/- embryos but normality of PIKfyve+/- mice.
Ikonomov OC; Sbrissa D; Delvecchio K; Xie Y; Jin JP; Rappolee D; Shisheva A
J Biol Chem; 2011 Apr; 286(15):13404-13. PubMed ID: 21349843
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of PIKfyve Leads to Lysosomal Disorders via Dysregulation of mTOR Signaling.
Xia J; Wang H; Zhong Z; Jiang J
Cells; 2024 May; 13(11):. PubMed ID: 38891085
[TBL] [Abstract][Full Text] [Related]
27. Distinct Requirements for Vacuolar Protein Sorting 34 Downstream Effector Phosphatidylinositol 3-Phosphate 5-Kinase in Podocytes Versus Proximal Tubular Cells.
Venkatareddy M; Verma R; Kalinowski A; Patel SR; Shisheva A; Garg P
J Am Soc Nephrol; 2016 Sep; 27(9):2702-19. PubMed ID: 26825532
[TBL] [Abstract][Full Text] [Related]
28. Loss of PIKfyve drives the spongiform degeneration in prion diseases.
Lakkaraju AKK; Frontzek K; Lemes E; Herrmann U; Losa M; Marpakwar R; Aguzzi A
EMBO Mol Med; 2021 Sep; 13(9):e14714. PubMed ID: 34291577
[TBL] [Abstract][Full Text] [Related]
29. The amyloid precursor protein (APP) binds the PIKfyve complex and modulates its function.
Currinn H; Wassmer T
Biochem Soc Trans; 2016 Feb; 44(1):185-90. PubMed ID: 26862204
[TBL] [Abstract][Full Text] [Related]
30. The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.
Baranov MV; Bianchi F; van den Bogaart G
Cells; 2020 Dec; 10(1):. PubMed ID: 33375410
[TBL] [Abstract][Full Text] [Related]
31. PtdIns5P: news and views of its appearance, disappearance and deeds.
Shisheva A
Arch Biochem Biophys; 2013 Oct; 538(2):171-80. PubMed ID: 23916588
[TBL] [Abstract][Full Text] [Related]
32. Selective insulin-induced activation of class I(A) phosphoinositide 3-kinase in PIKfyve immune complexes from 3T3-L1 adipocytes.
Sbrissa D; Ikonomov O; Shisheva A
Mol Cell Endocrinol; 2001 Jul; 181(1-2):35-46. PubMed ID: 11476939
[TBL] [Abstract][Full Text] [Related]
33. A mammalian ortholog of Saccharomyces cerevisiae Vac14 that associates with and up-regulates PIKfyve phosphoinositide 5-kinase activity.
Sbrissa D; Ikonomov OC; Strakova J; Dondapati R; Mlak K; Deeb R; Silver R; Shisheva A
Mol Cell Biol; 2004 Dec; 24(23):10437-47. PubMed ID: 15542851
[TBL] [Abstract][Full Text] [Related]
34. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Mandelkern T; Zheng M; Xu T; Rothberg J; Lichenstein H
Blood; 2017 Mar; 129(13):1768-1778. PubMed ID: 28104689
[TBL] [Abstract][Full Text] [Related]
35. A cell-permeable tool for analysing APP intracellular domain function and manipulation of PIKfyve activity.
Guscott B; Balklava Z; Safrany ST; Wassmer T
Biosci Rep; 2016; 36(2):. PubMed ID: 26934981
[TBL] [Abstract][Full Text] [Related]
36. ArPIKfyve homomeric and heteromeric interactions scaffold PIKfyve and Sac3 in a complex to promote PIKfyve activity and functionality.
Sbrissa D; Ikonomov OC; Fenner H; Shisheva A
J Mol Biol; 2008 Dec; 384(4):766-79. PubMed ID: 18950639
[TBL] [Abstract][Full Text] [Related]
37. Requirement for PIKfyve enzymatic activity in acute and long-term insulin cellular effects.
Ikonomov OC; Sbrissa D; Mlak K; Shisheva A
Endocrinology; 2002 Dec; 143(12):4742-54. PubMed ID: 12446602
[TBL] [Abstract][Full Text] [Related]
38. PIKfyve lipid kinase is a protein kinase: downregulation of 5'-phosphoinositide product formation by autophosphorylation.
Sbrissa D; Ikonomov OC; Shisheva A
Biochemistry; 2000 Dec; 39(51):15980-9. PubMed ID: 11123925
[TBL] [Abstract][Full Text] [Related]
39. PIKfyve and its Lipid products in health and in sickness.
Shisheva A
Curr Top Microbiol Immunol; 2012; 362():127-62. PubMed ID: 23086417
[TBL] [Abstract][Full Text] [Related]
40. PI4KA and PIKfyve: Essential phosphoinositide signaling enzymes involved in myriad human diseases.
Barlow-Busch I; Shaw AL; Burke JE
Curr Opin Cell Biol; 2023 Aug; 83():102207. PubMed ID: 37453227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
